Cancer Conversations Podcast – Episode #4: The Latest Research in Multiple Myeloma and Leukemia

Matthew Davids

Matthew Davids, MD, of Dana-Farber’s Hematologic Oncology Treatment Center.

With new research in immunotherapy and targeted therapy, treatment options for blood cancer patients are rapidly expanding. Combination therapies have also caused much excitement among researchers and physicians, and ongoing clinical trials are continuing to look at new strategies that use multiple drugs for fighting these diseases.

In this Cancer Conversations podcast episode, Irene Ghobrial, MD, and Matthew Davids, MD, of Dana-Farber’s Hematologic Oncology Treatment Center, discuss some of these new treatments and clinical trials for multiple myeloma, leukemia and other blood cancers.

Listen to the podcast episode below or click “download” to listen later. Subscribe options are also available via iTunes, Google Play and RSS.

The Cancer Conversations series features Q&A-style conversations with Dana-Farber physicians, clinicians, and researchers. Topics include breast cancer research, precision cancer medicine, integrative therapies, cancer genetics, and more. Visit the Cancer Conversations page for more episodes.

Learn more about Dana-Farber’s Cancer Podcast Series.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

Latest Tweets

Dana-Farber @danafarber
Having a child diagnosed with #cancer can be an overwhelming experience. Here's what you need to know:… https://t.co/mWwlToNcwI
Dana-Farber @danafarber
Fact check: Can breast lumps cause cancer? Women with breast implants have an increased, but still extremely low, r… https://t.co/bNPi8bH6wv
Dana-Farber @danafarber
5 Things to Know About Early #Cancer Detection: https://t.co/g0lFv5FC4E https://t.co/RCFvrUHR47

Patient and Family Blogs

Patients and families of patients at Dana-Farber often chronicle their own experiences with cancer.

Here are some blogs that you can follow.